AbbVie wants to become a major player in antibody-drug conjugates (ADCs) and is aiming to expand into prostate cancer with its novel dual-antigen targeting asset, ABBV-969.
This targets the well-known prostate-specific membrane antigen (PSMA) as well as another antigen which is overexpressed in prostate cancer, six-transmembrane epithelial antigen of the prostate 1 (STEAP1), and it carries...
Key Takeaways
- AbbVie is investing heavily in ADCs, and dual antigen targeting ABBV-969 is one of its most novel assets.
- The AACR presentation will...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?